author-photo

Hans D. Menssen

Novartis

16

Papers

1646

Citations

Citation Trend

Filter By

Papers (12) Sort By

Journal Conference Others

Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis.

2020 The Journal of Allergy and Clinical Immunology
Show All
- Source
- Cite
- Save
Citations (9)
Relative Bioavailability and Food Effect Evaluation for 2 Tablet Formulations of Asciminib in a 2‐Arm, Crossover, Randomized, Open‐Label Study in Healthy Volunteers

2019 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (5)
Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study

2017 Leukemia
Show All
- Source
- Cite
- Save
Citations (167)
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

2016 Leukemia
Show All
- Source
- Cite
- Save
Citations (463)
Treatment-free remission (TFR) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib: Results from the ENESTFreedom study.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

2014 Haematologica
Show All
- Source
- Cite
- Save
Citations (38)
Efficacy and Safety of Nilotinib (NIL) vs Imatinib (IM) in Patients (pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Long-Term Follow-Up (f/u) of ENESTnd

2014 Blood
Show All
- Source
- Cite
- Save
Citations (49)
Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (17)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

2014 Blood
Show All
- Source
- Cite
- Save
Citations (192)
Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

2013 Blood
Show All
- Source
- Cite
- Save
Citations (3)